Skip to main content

VCEL

Stock
Health Care
Biotechnology

Performance overview

VCEL Price
Price Chart

Forward-looking statistics

Beta
0.64
Risk
42.05%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.

Company info

SectorHealth Care
IndustryBiotechnology
Employees309
Market cap$2.2B

Fundamentals

Enterprise value$2.1B
Revenue$238.5M
Revenue per employee
Profit margin1.25%
Debt to equity33.72

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$0.05
Dividend per share
Revenue per share$4.84
Avg trading volume (30 day)$17M
Avg trading volume (10 day)$19M
Put-call ratio

Macro factor sensitivity

Growth+1.0
Credit+5.5
Liquidity+0.8
Inflation-2.0
Commodities-0.7
Interest Rates-3.4

Valuation

Dividend yield0.00%
PEG Ratio86.96
Price to sales8.81
P/E Ratio86.96
Enterprise Value to Revenue8.92
Price to book7.10

Upcoming events

Next earnings dayMay 8, 2025
Next dividend day
Ex. dividend day

News

Vericel Corporation (VCEL) Reports Q1 Loss, Misses Revenue Estimates

Vericel Corporation (VCEL) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.08 per share a year ago.

Zacks Investment Research (May 8, 2025)
Applied Digital, Vericel, Calavo Growers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Wednesday.

Benzinga (January 15, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free